Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets). Exclusive U.S. commercialization rights to LIBERVANT, targeting seizure clusters in epilepsy patients ages 2–5 and 12+.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive U.S. commercialization rights to LIBERVANT, targeting seizure clusters in epilepsy patients ages 2–5 and 12+
- $10.0M upfront fee, plus up to $47.5M in regulatory and commercial milestones
- Mid-teens royalties on annual U.S. net sales, creating an ongoing variable cost burden
- Aquestive remains exclusive manufacturer under a 20-year supply agreement, strengthening supply continuity but limiting sourcing flexibility
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Eton secured exclusive U.S. and territorial rights to LIBERVANT, expanding its specialty epilepsy portfolio
- LIBERVANT is an orphan-designated treatment for seizure clusters in epilepsy patients
- Supply agreement with Aquestive supports product availability, while creating ongoing supply obligations
- Commercial impact depends on launch timing, adoption and economics detailed in Item 1.01
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.